Induction and Enhancement of Immune Responses to Herpes Simplex Virus Type 2 in Humans by Use of a Recombinant Glycoprotein D Vaccine

Stephen E. Straus, Barbara Savarese, Michael Tigges, Alison G. Freifeld, Philip R. Krause, David M. Margolis, Jeffrey L. Meier, David P. Paar, Suzanne F. Adair, Dino Dina, Cornelia Dekker, Rae Lyn Burke, Stephen E. Straus, Barbara Savarese, Michael Tigges, Alison G. Freifeld, Philip R. Krause, David M. Margolis, Jeffrey L. Meier, David P. PaarSuzanne F. Adair, Dino Dina, Cornelia Dekker, Rae Lyn Burke

Research output: Contribution to journalArticle

55 Citations (Scopus)

Abstract

A vaccine for a chronic or recurrent viral infection should induce immune responses that protect against primary disease or that augment preexisting defenses sufficiently to diminish the likelihood of disease recurrence or progression. Such a vaccine was sought for genital herpes, a sexually transmitted infection of epidemic proportion. Vaccine containing recombinant herpes simplex virus type 2 glycoprotein D expressed in CHO cells was given repeatedly and safely to 24 human volunteers. In previously uninfected subjects, the vaccine induced primary antigen-specific and neutralizing antibody responses nearing or exceeding those seen at entry in subjects with genital herpes. Primary cellular immune responses were also evoked. Vaccination of previously seropositive subjects boosted antibody titers to levels that remained, for ⩾1 year, severalfold above those attained in recurrent genital herpes. Either the quantity or mode of presentation of antigen permitted this vaccine to exhibit previously unachieved immunogenicity, which may prove adequate for antiviral immunoprophylaxis or treatment of genital herpes.

Original languageEnglish (US)
Pages (from-to)1045-1052
Number of pages8
JournalJournal of Infectious Diseases
Volume167
Issue number5
DOIs
StatePublished - May 1993

Fingerprint

Herpes Genitalis
Human Herpesvirus 2
Glycoproteins
Vaccines
Synthetic Vaccines
CHO Cells
Antigen Presentation
Virus Diseases
Sexually Transmitted Diseases
Neutralizing Antibodies
Cellular Immunity
Antibody Formation
Antiviral Agents
Volunteers
Vaccination
Antigens
Recurrence
Antibodies
Therapeutics

ASJC Scopus subject areas

  • Immunology and Allergy
  • Infectious Diseases

Cite this

Induction and Enhancement of Immune Responses to Herpes Simplex Virus Type 2 in Humans by Use of a Recombinant Glycoprotein D Vaccine. / Straus, Stephen E.; Savarese, Barbara; Tigges, Michael; Freifeld, Alison G.; Krause, Philip R.; Margolis, David M.; Meier, Jeffrey L.; Paar, David P.; Adair, Suzanne F.; Dina, Dino; Dekker, Cornelia; Burke, Rae Lyn; Straus, Stephen E.; Savarese, Barbara; Tigges, Michael; Freifeld, Alison G.; Krause, Philip R.; Margolis, David M.; Meier, Jeffrey L.; Paar, David P.; Adair, Suzanne F.; Dina, Dino; Dekker, Cornelia; Burke, Rae Lyn.

In: Journal of Infectious Diseases, Vol. 167, No. 5, 05.1993, p. 1045-1052.

Research output: Contribution to journalArticle

Straus, SE, Savarese, B, Tigges, M, Freifeld, AG, Krause, PR, Margolis, DM, Meier, JL, Paar, DP, Adair, SF, Dina, D, Dekker, C, Burke, RL, Straus, SE, Savarese, B, Tigges, M, Freifeld, AG, Krause, PR, Margolis, DM, Meier, JL, Paar, DP, Adair, SF, Dina, D, Dekker, C & Burke, RL 1993, 'Induction and Enhancement of Immune Responses to Herpes Simplex Virus Type 2 in Humans by Use of a Recombinant Glycoprotein D Vaccine', Journal of Infectious Diseases, vol. 167, no. 5, pp. 1045-1052. https://doi.org/10.1093/infdis/167.5.1045
Straus, Stephen E. ; Savarese, Barbara ; Tigges, Michael ; Freifeld, Alison G. ; Krause, Philip R. ; Margolis, David M. ; Meier, Jeffrey L. ; Paar, David P. ; Adair, Suzanne F. ; Dina, Dino ; Dekker, Cornelia ; Burke, Rae Lyn ; Straus, Stephen E. ; Savarese, Barbara ; Tigges, Michael ; Freifeld, Alison G. ; Krause, Philip R. ; Margolis, David M. ; Meier, Jeffrey L. ; Paar, David P. ; Adair, Suzanne F. ; Dina, Dino ; Dekker, Cornelia ; Burke, Rae Lyn. / Induction and Enhancement of Immune Responses to Herpes Simplex Virus Type 2 in Humans by Use of a Recombinant Glycoprotein D Vaccine. In: Journal of Infectious Diseases. 1993 ; Vol. 167, No. 5. pp. 1045-1052.
@article{611a71290e2b46248f91837f55970865,
title = "Induction and Enhancement of Immune Responses to Herpes Simplex Virus Type 2 in Humans by Use of a Recombinant Glycoprotein D Vaccine",
abstract = "A vaccine for a chronic or recurrent viral infection should induce immune responses that protect against primary disease or that augment preexisting defenses sufficiently to diminish the likelihood of disease recurrence or progression. Such a vaccine was sought for genital herpes, a sexually transmitted infection of epidemic proportion. Vaccine containing recombinant herpes simplex virus type 2 glycoprotein D expressed in CHO cells was given repeatedly and safely to 24 human volunteers. In previously uninfected subjects, the vaccine induced primary antigen-specific and neutralizing antibody responses nearing or exceeding those seen at entry in subjects with genital herpes. Primary cellular immune responses were also evoked. Vaccination of previously seropositive subjects boosted antibody titers to levels that remained, for ⩾1 year, severalfold above those attained in recurrent genital herpes. Either the quantity or mode of presentation of antigen permitted this vaccine to exhibit previously unachieved immunogenicity, which may prove adequate for antiviral immunoprophylaxis or treatment of genital herpes.",
author = "Straus, {Stephen E.} and Barbara Savarese and Michael Tigges and Freifeld, {Alison G.} and Krause, {Philip R.} and Margolis, {David M.} and Meier, {Jeffrey L.} and Paar, {David P.} and Adair, {Suzanne F.} and Dino Dina and Cornelia Dekker and Burke, {Rae Lyn} and Straus, {Stephen E.} and Barbara Savarese and Michael Tigges and Freifeld, {Alison G.} and Krause, {Philip R.} and Margolis, {David M.} and Meier, {Jeffrey L.} and Paar, {David P.} and Adair, {Suzanne F.} and Dino Dina and Cornelia Dekker and Burke, {Rae Lyn}",
year = "1993",
month = "5",
doi = "10.1093/infdis/167.5.1045",
language = "English (US)",
volume = "167",
pages = "1045--1052",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "5",

}

TY - JOUR

T1 - Induction and Enhancement of Immune Responses to Herpes Simplex Virus Type 2 in Humans by Use of a Recombinant Glycoprotein D Vaccine

AU - Straus, Stephen E.

AU - Savarese, Barbara

AU - Tigges, Michael

AU - Freifeld, Alison G.

AU - Krause, Philip R.

AU - Margolis, David M.

AU - Meier, Jeffrey L.

AU - Paar, David P.

AU - Adair, Suzanne F.

AU - Dina, Dino

AU - Dekker, Cornelia

AU - Burke, Rae Lyn

AU - Straus, Stephen E.

AU - Savarese, Barbara

AU - Tigges, Michael

AU - Freifeld, Alison G.

AU - Krause, Philip R.

AU - Margolis, David M.

AU - Meier, Jeffrey L.

AU - Paar, David P.

AU - Adair, Suzanne F.

AU - Dina, Dino

AU - Dekker, Cornelia

AU - Burke, Rae Lyn

PY - 1993/5

Y1 - 1993/5

N2 - A vaccine for a chronic or recurrent viral infection should induce immune responses that protect against primary disease or that augment preexisting defenses sufficiently to diminish the likelihood of disease recurrence or progression. Such a vaccine was sought for genital herpes, a sexually transmitted infection of epidemic proportion. Vaccine containing recombinant herpes simplex virus type 2 glycoprotein D expressed in CHO cells was given repeatedly and safely to 24 human volunteers. In previously uninfected subjects, the vaccine induced primary antigen-specific and neutralizing antibody responses nearing or exceeding those seen at entry in subjects with genital herpes. Primary cellular immune responses were also evoked. Vaccination of previously seropositive subjects boosted antibody titers to levels that remained, for ⩾1 year, severalfold above those attained in recurrent genital herpes. Either the quantity or mode of presentation of antigen permitted this vaccine to exhibit previously unachieved immunogenicity, which may prove adequate for antiviral immunoprophylaxis or treatment of genital herpes.

AB - A vaccine for a chronic or recurrent viral infection should induce immune responses that protect against primary disease or that augment preexisting defenses sufficiently to diminish the likelihood of disease recurrence or progression. Such a vaccine was sought for genital herpes, a sexually transmitted infection of epidemic proportion. Vaccine containing recombinant herpes simplex virus type 2 glycoprotein D expressed in CHO cells was given repeatedly and safely to 24 human volunteers. In previously uninfected subjects, the vaccine induced primary antigen-specific and neutralizing antibody responses nearing or exceeding those seen at entry in subjects with genital herpes. Primary cellular immune responses were also evoked. Vaccination of previously seropositive subjects boosted antibody titers to levels that remained, for ⩾1 year, severalfold above those attained in recurrent genital herpes. Either the quantity or mode of presentation of antigen permitted this vaccine to exhibit previously unachieved immunogenicity, which may prove adequate for antiviral immunoprophylaxis or treatment of genital herpes.

UR - http://www.scopus.com/inward/record.url?scp=0027499198&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027499198&partnerID=8YFLogxK

U2 - 10.1093/infdis/167.5.1045

DO - 10.1093/infdis/167.5.1045

M3 - Article

C2 - 8387560

AN - SCOPUS:0027499198

VL - 167

SP - 1045

EP - 1052

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

IS - 5

ER -